THE WOODLANDS, Texas, April 21, 2008 (PRIME NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX) will release its first quarter 2008 financial results on Tuesday, April 29, 2008 after the financial markets close. Lexicon management will hold a conference call to discuss its clinical development progress and financial results for first quarter 2008 at 5:00 p.m. Eastern Time on April 29, 2008.
The dial-in number for the conference call is 866-316-1364 (within the United States) or 913-312-6667 (international). The pass code for all callers is 7581545. Investors can access a live webcast of the call at www.lexpharma.com. An archived version of the webcast will be available on the website through May 2, 2008.
About Lexicon
Lexicon is a leader in genomics-based drug discovery. Through its proprietary gene knockout technology, the company is dedicated to discovering and developing breakthrough treatments for human disease. Lexicon currently has development programs underway for such areas of major unmet medical need as irritable bowel syndrome, cognitive disorders, autoimmune diseases, and carcinoid syndrome. The company has used its proprietary gene knockout technology to discover more than 100 promising drug targets and create an extensive pipeline of clinical and preclinical programs in the therapeutic areas of cardiology, gastroenterology, immunology and oncology, metabolism, neurology and ophthalmology. To focus its commitment, Lexicon initiated its 10TO10 program to advance 10 new drug candidates into human clinical trials by the end of 2010. To advance the development and commercialization of its programs, Lexicon is working both independently and through collaborators including Bristol-Myers Squibb Company, Genentech, Inc. and N.V. Organon. For additional information about Lexicon and its programs, please visit www.lexpharma.com.
The Lexicon Pharmaceuticals, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=4799
Safe Harbor Statement
This press release contains "forward-looking statements," including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2007, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.